Journalists from The Paper learned at the site of the eighth round of China's national drug centralized procurement that BrightGene Pharmaceutical Co., Ltd., HEC CJ PHARM, Qilu Pharmaceutical Co., Ltd., Jiangsu Jiangfeng, Harbin Kanglong Pharmaceutical Co., Ltd., Suzhou Erye Pharmaceutical Co., Ltd., and Hetero are proposed to be selected for Oseltamivir/0.36g.
Borui Pharma, Dongyangguang, and Others Secure Tentative Selection in China's 8th Batch National Drug Centralized Procurement for Oseltamivir
Mar 29, 2023 14:36
CST Updated
14:36
Yichang HEC Changjiang Pharmaceutical
Therapeutic Area Product Development and Manufacturing
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Hetero
Key Active Pharmaceutical Ingredients (API) and Generic Drug Manufacturers